Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation

被引：1
|
作者：
Bouwhuis, M. G.
Suciu, S.
Testori, A.
Santinami, M.
Kruit, W. H.
Punt, C. J.
Sales, F.
Patel, P. M.
Spatz, A.
Eggermont, A. M. M.
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands
[2] EORTC Data Ctr, Dept Biostat, Brussels, Belgium
[3] European Inst Oncol, Milan, Italy
[4] Natl Canc Inst, I-20133 Milan, Italy
[5] Univ Med Ctr Nijmegen, Nijmegen, Netherlands
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[8] Inst Gustave Roussy, Villejuif, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1359-6349(07)70098-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5LB
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [1] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Eggermont, Alexander M. M.
    Bouwhuis, Marna G.
    Kruit, Wim H.
    Testori, Alessandro
    ten Hagen, Timo
    Yver, Antoine
    Xu, Christine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 671 - 677
  • [2] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Alexander M. M. Eggermont
    Marna G. Bouwhuis
    Wim H. Kruit
    Alessandro Testori
    Timo ten Hagen
    Antoine Yver
    Christine Xu
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 65 : 671 - 677
  • [3] Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies-EORTC 18991
    Bouwhuis, Marna G.
    Suciu, Stefan
    Testori, Alessandro
    Kruit, Wim H.
    Sales, Francois
    Patel, Poulam
    Punt, Cornelis J.
    Santinami, Mario
    Spatz, Alain
    ten Hagen, Timo L. M.
    Eggermont, Alexander M. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : 2460 - 2466
  • [4] Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial
    Eggermont, A. M. M.
    Suciu, S.
    Santinami, M.
    Testori, A.
    Kruit, W.
    Marsden, J.
    Punt, C. J. A.
    Sales, F.
    Gore, M.
    Mckie, R.
    Kusic, V.
    Dummer, R.
    Musat, E.
    Spatz, A.
    Keilholz, U.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 290 - 290
  • [5] EORTC 18991:: long term adjuvant pegylated interferon-α2b (PEG-IFN) vs observation in resected stage III melanoma:: final results of a randomized phase 3 trial
    Eggermont, A. M. M.
    Suciu, S.
    Santinami, M.
    Kruit, W.
    Testori, A.
    Marsden, J.
    Punt, C. J. A.
    Hauschild, A.
    Gore, M.
    Keilholz, U.
    [J]. ARCHIVES OF DERMATOLOGICAL RESEARCH, 2007, 299 (5-6) : 298 - 299
  • [6] Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Testori, Alessandro
    Santinami, Mario
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Dummer, Reinhard
    Robert, Caroline
    Schadendorf, Dirk
    Patel, Poulam M.
    de Schaetzen, Gaetan
    Spatz, Alan
    Keilholz, Ulrich
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3810 - 3818
  • [7] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Santinami, Mario
    Testori, Alessandro
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Gore, Martin
    MacKie, Rona
    Kusic, Zvonko
    Dummer, Reinhard
    Hauschild, Axel
    Musat, Elena
    Spatz, Alain
    Keilholz, Ulrich
    [J]. LANCET, 2008, 372 (9633): : 117 - 126
  • [8] EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial
    Eggermont, A. M.
    Suciu, S.
    Santinami, M.
    Kruit, W.
    Testori, A.
    Marsden, J.
    Punt, C.
    Hauschild, A.
    Gore, M.
    Keilholz, U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Testori, Alessandro
    Kruit, Wim H.
    Marsden, Jeremy
    Punt, Cornelis J.
    Santinami, Mario
    Sales, Francois
    Schadendorf, Dirk
    Patel, Poulam
    Dummer, Reinhard
    Robert, Caroline
    Keilholz, Ulrich
    Yver, Antoine
    Spatz, Alan
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 218 - 225
  • [10] EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up
    Eggermont, A. M.
    Suciu, S.
    Santinami, M.
    Kruit, W.
    Testori, A.
    Marsden, J.
    Punt, C. J. A.
    Gore, M. E.
    MacKie, R.
    Dummer, R.
    Schadendorf, D.
    Patel, P.
    Spatz, A.
    Keilholz, U.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345